Diversified Business ModelA multi-segment footprint across APIs, finished dosages and specialty chemicals provides structural diversification. This reduces dependency on any single end market, supports cross-selling, and helps stabilize revenues and capacity utilization over a multi-month horizon.

Contract Manufacturing PartnershipsLong-term manufacturing contracts and collaborations leverage in-house production capabilities and create recurring revenue streams. Such partnerships can lock in utilization, provide predictable volumes, and act as a durable revenue base versus one-off sales.

Export And Licensing ExposureExposure to international markets and licensing deals diversifies demand geographically and product-wise. Access to exports and licenses supports longer-term growth opportunities and cushions domestic cyclical weakness, aiding resilience over several months.

Bears Say

Declining Revenue And Collapsing MarginsSustained revenue decline and a dramatic margin contraction indicate weakening pricing power, adverse product mix, or cost pressures. These impair operating leverage and the company's ability to generate profits or reinvest, harming long-term competitive positioning.

Negative Equity And Elevated LeverageNegative shareholder equity and extreme leverage raise solvency concerns and constrain strategic flexibility. High indebtedness limits access to affordable financing, increases refinancing risk, and can force asset sales or restructuring if cash flows don't recover.

Weak Operating And Free Cash FlowPersistent negative operating and free cash flows undermine the company's ability to service debt, fund capex, or invest in growth without external financing. Deteriorating cash generation is a durable red flag for sustainability absent structural turnaround.

Vivimed Labs Limited News

Vivimed Labs’ Debt Assigned to Rare Asset Reconstruction Ltd.

Vivimed Labs Limited ( ($IN:VIVIMEDLAB) ) has provided an announcement. Vivimed Labs Limited has announced that Rare Asset...

4M ago

Vivimed Labs Reports Financial Results Amid Loan Default Challenges

Vivimed Labs Limited ( ($IN:VIVIMEDLAB) ) has shared an update. Vivimed Labs Limited’s Board of Directors approved several...

6M ago

VIVIMEDLAB FAQ

What was Vivimed Labs Limited’s price range in the past 12 months?

Vivimed Labs Limited lowest stock price was ₹4.88 and its highest was ₹27.99 in the past 12 months.

What is Vivimed Labs Limited’s market cap?

Vivimed Labs Limited’s market cap is ₹608.59M.

When is Vivimed Labs Limited’s upcoming earnings report date?

Vivimed Labs Limited’s upcoming earnings report date is May 29, 2026 which is in 96 days.

How were Vivimed Labs Limited’s earnings last quarter?

Currently, no data Available

Is Vivimed Labs Limited overvalued?

According to Wall Street analysts Vivimed Labs Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Vivimed Labs Limited pay dividends?

Vivimed Labs Limited pays a Annually dividend of ₹0.4 which represents an annual dividend yield of N/A. See more information on Vivimed Labs Limited dividends here

What is Vivimed Labs Limited’s EPS estimate?

Vivimed Labs Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Vivimed Labs Limited have?

Vivimed Labs Limited has 82,913,910 shares outstanding.

What happened to Vivimed Labs Limited’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Vivimed Labs Limited?

Currently, no hedge funds are holding shares in IN:VIVIMEDLAB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Vivimed Labs Limited

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India, Mexico, Spain, Hungary, and internationally. It operates in two segments, Specialty Chemicals Business and Pharma Business. The company provides APIs and intermediates to generic and ethical companies; and branded formulations in therapeutic segments, such as ophthalmic, nutraceuticals, dermatology, and pain, as well as contract manufacturing of capsules and tablets, syrups and liquids, and nasal sprays and ointments. It also offers a range of hair dye intermediates for use in permanent, semi-permanent, and temporary hair colorant systems; oxidation dye couplers and bases to formulate various permanent and demi-permanent shades; direct dyes for semi-permanent formulations; and basic dyes for temporary, semi-permanent, and color-refresher shampoos and conditioners under the Jarocol name. In addition, the company manufactures and markets photochromic dyes under the Reversacol name; and anti-microbial actives for use in a range of applications, including plastics additives and anti-bacterial handwashes. Further, it offers photographic chemicals, such as black and white developers, and antifog additives for use in medical and industrial X-ray imaging, consumer photography, and litho-plate production for the graphic arts industry. Additionally, the company manufactures Favulous for the treatment of mild to moderate cases of Covid-19. Its products are used in home, personal, and industrial care segments. The company was incorporated in 1988 and is based in Hyderabad, India.